Skip to search formSkip to main contentSkip to account menu

IMGN853

National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antibodies, Monoclonal, HumanizedImmunoconjugatesMaytansineMirvetuximab Soravtansine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast…
3009 Background: IMGN853 is an antibody-drug conjugate targeting the folate receptor alpha (FOLR1), linked to maytansinoid, DM4… 
2017
2017
Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with…
5553Background: FORWARD II is a phase 1b study of the FRα-targeting ADC, mirvetuximab soravtansine (IMGN853), in combination with… 
2017
2017
Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety…
5547Background: The early clinical evaluation of mirvetuximab soravtansine (IMGN853), an ADC that comprises a FRα-binding… 
2017
2017
The KRAS Membrane Anchor Regulates Signaling through Lipid Specificity.
KRAS lipid specificity controls signaling and is not determined solely by electrostatic attraction. 
2016
2016
IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).
5567Background: IMGN853 (mirvetuximab soravtansine) is an ADC, comprising a FRα-binding antibody linked to the tubulin-disrupting… 
2015
2015
Preliminary single agent activity of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase…
5518 Background: IMGN853 (mirvetuximab soravtansine) is a FRα-targeting ADC that comprises a FRα-binding antibody conjugated with… 
2015
2015
Abstract C47: Association of folate receptor alpha (FRα) expression level and clinical activity of IMGN853 (mirvetuximab soravtansine), a FRα-targeting antibody-drug conjugate (ADC), in FR…
Background: IMGN853 is a FRα-targeting ADC comprising a FRα-binding antibody conjugated with the potent maytansinoid, DM4, a… 
2014
2014
Abstract 4641: Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting…
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA IMGN853 is an antibody-drug conjugate (ADC) that binds… 
2011
2011
Abstract 1760: Preclinical evaluation of IMGN853, an anti-FOLR1 antibody-maytansinoid conjugate, as a potential therapeutic for ovarian cancer
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL IMGN853 (M9346A-sulfo-SPDB-DM4) is an antibody drug… 
2011
2011
Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Previously we reported (O. Ab; EORTC, 2010) that an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)